Current Treatment Landscape for Patients with Lower-Risk MDS

Now Viewing

EP: 1.Current Treatment Landscape for Patients with Lower-Risk MDS

EP: 2.MDS: Transfusion Independence Across Different Risk Subgroups in IMerge Phase 3 Trial

EP: 3.Impact of Mutational Status on Response in IMerge Phase 3 Study in MDS

EP: 4.Durable Transfusion Independence in Lower-Risk MDS

EP: 5.MDS: Patient-Reported Outcomes and Imetelstat Toxicity in IMerge Phase 3 Trial

EP: 6.Biomarker Analysis and Patient-Reported Outcomes from COMMANDS Study in MDS

EP: 7.MDS: Canakinumab Phase 1b/2 Study

EP: 8.Clinical Implications of Recent Data in MDS

This is a video synopsis of a discussion featuring Gary J. Schiller, MD, chief of the Hematological Malignancy/Stem Cell Transplantation program at the David Geffen School of Medicine at UCLA Health Jonsson Comprehensive Cancer Center.

Gary Schiller, MD, PhD, Chief of the Hematologic Malignancy/Stem Cell Transplantation Program at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) stated that low risk myelodysplastic syndromes (MDS) is still a heterogeneous group in terms of the molecular basis of the disease and the clinical manifestations.

Dr Schiller said that for the vast majority of patients, transfusion-dependent anemia is the major problem, although other cytopenias can also present in low risk MDS. Cytopenias refer to low blood cell counts.

Another feature often seen in low risk MDS is inflammation, according to Dr Schiller. This can be associated with fatigue, but also clinical symptoms such as joint pain, muscle pain, exertional fatigue, and skin rash. Typically, there are features both related to low blood counts as well as general performance status associated with low risk MDS.

*Video synopsis is AI-generated and reviewed by Targeted Oncology editorial staff.